Evolus (EOLS) Asset Writedowns and Impairment (2019 - 2025)
Evolus (EOLS) posted Asset Writedowns and Impairment of $2.2 million for Q3 2025, up 214.37% on a QoQ basis from $703000.0 in Q2 2025, and up 148.59% year-over-year from $889000.0 in Q3 2024.
Evolus (EOLS) Asset Writedowns and Impairment (2019 - 2025) Analysis & Trends
Evolus' Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $2.2 million for Q3 2025.
- Quarterly Asset Writedowns and Impairment rose 148.59% year-over-year to $2.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.8 million (up 172.44% YoY) and the FY2024 annual result came in at $2.4 million, up 70.07% from the prior year.
- Asset Writedowns and Impairment was $2.2 million for Q3 2025 at Evolus, up from $703000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $2.2 million in Q3 2025 and bottomed at -$297000.0 in Q2 2021.
- A 5-year average of $528421.1 and a median of $465000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment sank 76.6% — and 2024, when it soared 818.6%.
- Evolus' Asset Writedowns and Impairment stood at $88000.0 in 2021, then soared by 167.05% to $235000.0 in 2022, then sank by 63.4% to $86000.0 in 2023, then surged by 818.6% to $790000.0 in 2024, then jumped by 179.75% to $2.2 million in 2025.
- Business Quant data shows EOLS's Asset Writedowns and Impairment at $2.2 million in Q3 2025, $703000.0 in Q2 2025, and $1.1 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.21 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 703,000.00 |
| Jun 30, 2025 | 703,000.00 |
| Mar 31, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 790,000.00 |
| Dec 31, 2024 | 790,000.00 |
| Sep 30, 2024 | 889,000.00 |
| Sep 30, 2024 | 889,000.00 |
| Jun 30, 2024 | 582,000.00 |
| Jun 30, 2024 | 582,000.00 |
| Mar 31, 2024 | 188,000.00 |
| Mar 31, 2024 | 188,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Sep 30, 2023 | 1.01 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | 69,000.00 |
| Jun 30, 2023 | 69,000.00 |